Drug Information

Drug (ID: DG00351) and It's Reported Resistant Information

• Name: NSC141562
• Synonyms: NSC141562; NSC-141562; CHEMBL2003340; 1-[(2-methylquinolin-3-yl)methyl]-3,7-triaza-1-azoniatricyclo[3.3.1.13,7]decane, bromide
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Brain cancer [ICD-11: 2A00]; [1]
• Formula: C17H22BrN5
• IsoSMILES: CC1=NC2=CC=CC=C2C=C1C[N+]34CN5CN(C3)CN(C5)C4.[Br-]
• InChI: 1S/C17H22N5.BrH/c1-14-16(6-15-4-2-3-5-17(15)18-14)7-22-11-19-8-20(12-22)10-21(9-19)13-22;/h2-6H,7-13H2,1H3;1H/q+1;/p-1
• InChIKey: IYASYYOEAXFOPQ-UHFFFAOYSA-M
• PubChem CID: 5458295

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: hsa-mir-155 [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Malignant glioma [ICD-11: 2A00.2]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Epithelial mesenchymal transition signaling pathway; Activation; hsa01521
• Cell Pathway Regulation: Wnt/beta-catenin signaling pathway; Activation; hsa04310
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• In Vitro Model: U87 cells; Brain; Homo sapiens (Human); CVCL_0022
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: CCK8 assay; Wound healing assay; Transwell assay; MTT assay
• Mechanism Description: miR155HG Is a Mesenchymal Transition-Associated Long Noncoding RNA, miR155-5p and miR155-3p Are key Derivatives of MIR155HG. miR155-5p or miR155-3p Targets Protocadherin 9 or 7, Respectively, Protocadherin 9 and 7 Function as Tumor Suppressor Genes by Inhibiting the Wnt/ beta-catenin signaling pathway.

Key Molecule: MIR155 host gene (MIR155HG) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Malignant glioma [ICD-11: 2A00.2]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Epithelial mesenchymal transition signaling pathway; Activation; hsa01521
• Cell Pathway Regulation: Wnt/beta-catenin signaling pathway; Activation; hsa04310
• In Vitro Model: U251 cells; Brain; Homo sapiens (Human); CVCL_0021
• In Vitro Model: U87 cells; Brain; Homo sapiens (Human); CVCL_0022
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: qPCR; Microarray assay
• Experiment for Drug Resistance: CCK8 assay; Wound healing assay; Transwell assay; MTT assay
• Mechanism Description: miR155HG Is a Mesenchymal Transition-Associated Long Noncoding RNA, miR155-5p and miR155-3p Are key Derivatives of MIR155HG. miR155-5p or miR155-3p Targets Protocadherin 9 or 7, Respectively, Protocadherin 9 and 7 Function as Tumor Suppressor Genes by Inhibiting the Wnt/ beta-catenin signaling pathway.

References

• Ref 1: Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neuro Oncol. 2017 Sep 1;19(9):1195-1205. doi: 10.1093/neuonc/nox017.